(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 41.87% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Axsome Therapeutics's revenue in 2026 is $776,569,000.On average, 25 Wall Street analysts forecast AXSM's revenue for 2026 to be $51,084,916,563, with the lowest AXSM revenue forecast at $44,894,027,683, and the highest AXSM revenue forecast at $56,623,664,258. On average, 25 Wall Street analysts forecast AXSM's revenue for 2027 to be $81,242,648,718, with the lowest AXSM revenue forecast at $59,556,990,066, and the highest AXSM revenue forecast at $96,014,039,394.
In 2028, AXSM is forecast to generate $117,228,270,684 in revenue, with the lowest revenue forecast at $85,590,256,612 and the highest revenue forecast at $152,899,607,742.